文章摘要
张拥军1 范久波2△ 李青锋3 胡知朋1 杨俊波1.多西紫杉醇联合适形放疗治疗老年贲门癌患者的疗效观察[J].,2012,12(3):525-526
多西紫杉醇联合适形放疗治疗老年贲门癌患者的疗效观察
Weekly Docetaxel and Concomitant Radiotherapy for the Elderly Patientswith Unresectable Gastric Cancer
  
DOI:
中文关键词: 进展期贲门癌  周剂量多西紫杉醇  三维适形放疗
英文关键词: Advanced gastric cancer  Weekly docetaxel  3DCRT
基金项目:
作者单位
张拥军1 范久波2△ 李青锋3 胡知朋1 杨俊波1 湖北省襄阳市中心医院 
摘要点击次数: 870
全文下载次数: 0
中文摘要:
      目的:探讨周剂量多西紫杉醇联合三维适形放疗(3DCRT)治疗进展期贲门癌患者的疗效。方法:2007 年10 月到2009 年5 月38 例不能手术的贲门癌患者行3DCRT,处方剂量62Gy,1.8Gy/次,5 次/周;同时联合多西紫杉醇75mg/m2,每周1 次,连续 6 周。用Kaplan-Meier 法分析患者的中位无进展生存时间。结果:完全缓解12 例,部分缓解18 例,30 名患者缓解(78.9%),中位无 进展生存时间16.4 个月。治疗过程中的毒副作用轻,患者可以耐受。结论:周剂量多西紫杉醇化疗联合适形放疗对进展期贲门癌 患者是安全、有效的。
英文摘要:
      Objective: To explore the efficacy of weekly docetaxel and concurrent 3DCRT in treatment of elderly patients with unresectable gastric cancer.Methods: During October 2007 to May 2009,38 patients treated with 3DCRT (62 Gy in fractions of 1.8Gy daily, five times weekly) and concurrent docetaxel (75 mg/m2, one time per week for successive six weeks) .The Kaplan-Meier method was used to evaluate the median progression-free survival time. Results: Complete response and partial response were observed in 78.9% of patients. The overall median progression-free survival time was 16.4 months. Toxicities are tolerable. Conclusions: The therapy of 3DCRT plus concomitant chemotherapy based on docetaxel weekly was effective and safe for the treatment of unresectable gastric cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭